Wild-type JAK2 Secondary acute erythroleukemia developing after JAK2-V617F-Mutated primary myelofibrosis

Acta Haematologica

Volumn 122, Issue 1, 2009, Pages 36-38

  Kreft, Andreas ^a   Springer, Erik ^a   Lipka, Daniel B ^b   Kirkpatrick, Charles J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Erythroleukemia, secondary; JAK2 V617F mutation; Myelofibrosis; Primary

Indexed keywords

ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2;

ACUTE DISEASE; ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL ASSESSMENT; ERYTHROID CELL; ERYTHROLEUKEMIA; FEMALE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; MICRODISSECTION; MORPHOLOGY; MYELOID METAPLASIA; PRIORITY JOURNAL; WILD TYPE;

CELL TRANSFORMATION, NEOPLASTIC; FATAL OUTCOME; FEMALE; HUMANS; JANUS KINASE 2; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MIDDLE AGED; PRIMARY MYELOFIBROSIS;

EID: 69149106235     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235773     Document Type: Article

References (7)

1. Hussein K, Bock O, Kreipe H: Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers. Pathobiology 2007; 74: 72-80.
2. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC: Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375-379.
3. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ: The erythropoietin receptor in normal and cancer tissue. Crit Rev Oncol Hematol 2008; 67: 31-61.
4. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nuñez G, Fernandez-Luna JL: Erythropoietin can induce the expression of Bcl-x L through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999; 274: 22165-22169.
5. Kreft A, Burg J, Fischer T, Kirkpatrick CJ: Essential thrombocythemia terminating in pure erythroleukemia. Am J Hematol 2004; 77: 140-143.
6. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed 4. Lyon, IARC Press, 2008.
7. Fröhling S, Lipka DB, Kayser S, Scholl C, Schlenk RF, Döhner H, Gilliland DG, Levine RL, Döhner K: Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 2006; 107: 1242-1243.